Welcome to our dedicated page for Purple Biotech news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech stock.
Purple Biotech Ltd. develops oncology immunotherapies as a clinical-stage biotechnology company with American depositary shares traded under PPBT. Its recurring updates center on CAPTN-3, a platform of capped or masked tri-specific antibodies designed to target tumor-associated antigens while engaging both T cells and NK cells in the tumor microenvironment.
Company news commonly covers preclinical data, toxicology and manufacturing work for IM1240, the 5T4-targeting lead CAPTN-3 antibody, and IM1305, the TROP2-targeting development candidate. Other recurring themes include oncology research collaborations, scientific advisory activity, financial results, ADR and capital-structure actions, Nasdaq listing compliance, and governance updates.
Purple Biotech, trading under the ticker PPBT on NASDAQ/TASE, has announced the presentation of new preclinical data on NT219, a dual inhibitor targeting IRS1/2 and STAT3. This data will be showcased at the AACR 2021 Annual Meeting from April 10-15 and May 17-21. The study highlights the significant role of IRS2 in colorectal cancer brain metastasis and suggests NT219’s potential in addressing this issue. Ongoing trials for NT219 as a treatment for solid tumors aim to deliver top-line data by late 2021.
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) appointed Robert Gagnon to its Board of Directors, bringing 15 years of corporate finance expertise, primarily in biotech. Gagnon will serve until the 2022 annual general meeting. His appointment aims to leverage his experience as the company approaches key clinical milestones for anti-cancer therapies CM24 and NT219. Gagnon, currently Chief Business and Financial Officer at Verastem Oncology, has held significant financial roles at several biotech firms. This leadership change may enhance strategic direction and drive shareholder value.
Purple Biotech (PPBT) announced significant advancements in its anti-cancer therapies and financial results for 2020. Key highlights include the completion of patient recruitment for the NT219 clinical trial and imminent Phase 1b/2 studies for CM24. The company raised $68.5 million in 2020, ending with $60.8 million in cash, sufficient to support operations until 2024. Despite increased R&D expenses leading to a higher operating loss of $12.6 million, cash resources appear robust, supporting ongoing clinical initiatives aimed at improving cancer treatment outcomes.